CN110993092B - Ngfp诊断指标的获取方法和高危hcc预测模型的构建方法 - Google Patents
Ngfp诊断指标的获取方法和高危hcc预测模型的构建方法 Download PDFInfo
- Publication number
- CN110993092B CN110993092B CN201910980651.4A CN201910980651A CN110993092B CN 110993092 B CN110993092 B CN 110993092B CN 201910980651 A CN201910980651 A CN 201910980651A CN 110993092 B CN110993092 B CN 110993092B
- Authority
- CN
- China
- Prior art keywords
- log
- hcc
- ngfp
- sugar
- abundance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 14
- 238000010276 construction Methods 0.000 title claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims abstract description 41
- 210000002966 serum Anatomy 0.000 claims abstract description 19
- 238000005251 capillar electrophoresis Methods 0.000 claims abstract description 7
- 238000005516 engineering process Methods 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 7
- 238000012216 screening Methods 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 241001088532 Alyxia ruscifolia Species 0.000 claims description 2
- 102000004506 Blood Proteins Human genes 0.000 claims description 2
- 108010017384 Blood Proteins Proteins 0.000 claims description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 238000007477 logistic regression Methods 0.000 claims description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract description 35
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 33
- 201000007270 liver cancer Diseases 0.000 abstract description 8
- 208000014018 liver neoplasm Diseases 0.000 abstract description 8
- 206010016654 Fibrosis Diseases 0.000 abstract description 7
- 238000001514 detection method Methods 0.000 abstract description 7
- 230000007882 cirrhosis Effects 0.000 abstract description 6
- 102000003886 Glycoproteins Human genes 0.000 abstract description 4
- 108090000288 Glycoproteins Proteins 0.000 abstract description 4
- 238000013399 early diagnosis Methods 0.000 abstract description 4
- 238000003748 differential diagnosis Methods 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000029783 sperm-egg recognition Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910980651.4A CN110993092B (zh) | 2019-10-15 | 2019-10-15 | Ngfp诊断指标的获取方法和高危hcc预测模型的构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910980651.4A CN110993092B (zh) | 2019-10-15 | 2019-10-15 | Ngfp诊断指标的获取方法和高危hcc预测模型的构建方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110993092A CN110993092A (zh) | 2020-04-10 |
CN110993092B true CN110993092B (zh) | 2024-06-18 |
Family
ID=70082035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910980651.4A Active CN110993092B (zh) | 2019-10-15 | 2019-10-15 | Ngfp诊断指标的获取方法和高危hcc预测模型的构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110993092B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111477268B (zh) * | 2020-05-12 | 2024-02-06 | 北京世纪沃德生物科技有限公司 | 一种糖蛋白n-糖组图谱模型的建立方法及应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102707062A (zh) * | 2011-03-27 | 2012-10-03 | 上海交通大学附属第一人民医院 | 检测慢性乙肝肝纤维化血清n-糖组峰标记的方法及其用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1759320B (zh) * | 2003-01-14 | 2014-10-15 | Vib研究所 | 检测肝纤维化的血清标记 |
KR101520614B1 (ko) * | 2013-07-25 | 2015-05-19 | 서울대학교산학협력단 | 당단백질의 탈당화 검출을 통한 암 진단 방법 |
CN105452865A (zh) * | 2013-08-06 | 2016-03-30 | 金弦起 | 小肝细胞癌和潜伏于肝硬化的肝细胞癌诊断用组合物 |
CN108504739A (zh) * | 2018-05-15 | 2018-09-07 | 浙江大学 | 一种用于肝癌早期诊断的生物标志物及其应用 |
-
2019
- 2019-10-15 CN CN201910980651.4A patent/CN110993092B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102707062A (zh) * | 2011-03-27 | 2012-10-03 | 上海交通大学附属第一人民医院 | 检测慢性乙肝肝纤维化血清n-糖组峰标记的方法及其用途 |
Non-Patent Citations (1)
Title |
---|
原发性肝细胞癌患者血清N-糖组的表达分析;赵云鹏;高春芳;房萌;孙树汉;刘艳;陈冬梅;蔡美琳;;第二军医大学学报;20071220(第12期);1280-1283 * |
Also Published As
Publication number | Publication date |
---|---|
CN110993092A (zh) | 2020-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102565318B (zh) | 一种肝癌监测、分期以及预后风险评估的试剂及其方法 | |
CN114457192B (zh) | 对唾液中EB病毒CpG位点进行甲基化分型的试剂在制备鼻咽癌诊断试剂盒中的应用 | |
CN111812078A (zh) | 基于表面增强拉曼光谱的人工智能辅助***肿瘤早期诊断方法 | |
CN110993098A (zh) | 一种新型血液多指标肝癌诊断模型(gap-talad)的建立和应用 | |
CN109557311A (zh) | 结直肠癌诊断标志物及结直肠癌的检测产品及其应用 | |
CN111833963A (zh) | 一种cfDNA分类方法、装置和用途 | |
CN107435062A (zh) | 甄别肺部微小结节良恶性的外周血基因标志物及其用途 | |
CN111141807A (zh) | 一种基于血清n-糖指纹图谱鉴别肝硬化的方法 | |
CN108796075A (zh) | 检测circRNF13和LOC284454试剂的应用及试剂盒 | |
CN110993092B (zh) | Ngfp诊断指标的获取方法和高危hcc预测模型的构建方法 | |
CN108660215A (zh) | 检测circMAN1A2和circRNF13试剂的应用及试剂盒 | |
CN114574587A (zh) | 一种用于结直肠癌检测的标记物组合物及其应用 | |
CN111477268B (zh) | 一种糖蛋白n-糖组图谱模型的建立方法及应用 | |
CN116794330B (zh) | 用于酒精性肝病诊断的生物标志物及其应用 | |
CN113373222A (zh) | 一种用于胰腺导管腺癌的早筛评估方法 | |
CN105648075A (zh) | 一种肝癌诊断组合及含有该组合的试剂盒 | |
CN113470813A (zh) | 肝癌患者生存率预后模型 | |
CN113436673A (zh) | 一种用于肝癌预后预测的分子标志物及其应用 | |
CN114791459B (zh) | 用于检测肺结核的血清代谢标志物及其试剂盒 | |
CN116189904A (zh) | 一种分化型甲状腺癌的基因甲基化诊断模型及其构建方法 | |
CN1654953A (zh) | 构建肝癌蛋白质组指纹图谱模型的方法及其血清检测应用 | |
CN115261476A (zh) | 筛选血清外泌体LncRNA HULC作为肝癌早期标记物的方法及其制备试剂盒的用途 | |
CN117316278A (zh) | 一种基于cfDNA片段长度分布特征的癌症无创早筛方法及*** | |
CN108660213A (zh) | 检测三种非编码rna试剂的应用及试剂盒 | |
CN113450917A (zh) | 生物标志物在预测肝癌预后中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240320 Address after: 200437 Shanghai city Hongkou District Gan Road No. 110 Applicant after: YUEYANG HOSPITAL OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE SHANGHAI University OF TRADITIONAL CHINESE MEDICINE Country or region after: China Address before: 200438 Experimental Diagnosis Department, Building 1, No. 225 Changhai Road, Yangpu District, Shanghai Applicant before: Gao Chunfang Country or region before: China |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |